| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.48▲ | 6.41▲ | 6.48▲ | 6.31▲ | 7.53▼ |
| MA10 | 6.45▲ | 6.52▲ | 6.52▲ | 6.51▲ | 9.13▼ |
| MA20 | 6.51▲ | 6.43▲ | 6.33▲ | 7.51▼ | 8.33▼ |
| MA50 | 6.39▲ | 6.21▲ | 6.26▲ | 8.97▼ | N/A |
| MA100 | 6.26▲ | 6.42▲ | 7.16▼ | 8.20▼ | N/A |
| MA200 | 6.20▲ | 7.66▼ | 8.71▼ | 8.22▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.024▼ | 0.024▲ | -0.066▼ | -0.352▼ |
| RSI | 54.777▲ | 55.423▲ | 55.299▲ | 35.845▼ | 42.034▼ |
| STOCH | 54.603 | 10.208▼ | 55.843 | 24.732 | 33.471 |
| WILL %R | -20.000▲ | -56.522 | -32.500 | -68.902 | -83.205▼ |
| CCI | 81.841 | -18.106 | 40.909 | -41.189 | -115.438▼ |
|
Friday, June 06, 2025 04:11 PM
Actuate Therapeutics (NASDAQ:ACTU) on Saturday announced encouraging results from a Phase 2 clinical trial testing its experimental cancer drug, elraglusib, in combination with standard ...
|
|
Saturday, May 31, 2025 05:34 PM
Actuate Therapeutics, Inc. (NASDAQ:ACTU) plans to engage with the FDA later this year to discuss the path to registration, aiming to bring this first-in-class GSK-3β inhibitor therapy to patients ...
|
|
Saturday, May 31, 2025 01:30 PM
CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 03/07/25 | 6.76 | 6.7909 | 6.2816 | 6.59 | 53,843 |
| 02/07/25 | 6.10 | 6.87 | 6.03 | 6.74 | 128,574 |
| 01/07/25 | 6.38 | 6.39 | 5.80 | 6.13 | 260,628 |
| 30/06/25 | 5.88 | 6.7499 | 5.60 | 6.11 | 245,218 |
| 27/06/25 | 6.50 | 6.50 | 5.50 | 5.96 | 967,200 |
| 26/06/25 | 6.74 | 6.74 | 5.70 | 5.82 | 77,013 |
| 25/06/25 | 6.51 | 6.6893 | 6.225 | 6.44 | 52,972 |
| 24/06/25 | 7.29 | 7.29 | 6.65 | 6.75 | 96,925 |
| 23/06/25 | 7.35 | 7.37 | 6.86 | 7.05 | 84,100 |
| 20/06/25 | 8.04 | 8.90 | 7.27 | 7.47 | 507,400 |
|
|
||||
|
|
||||
|
|